At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 134 enrolled
Drug / intervention
Intravenous infusion of human albumin +1 moredrug
Likely dose
Intravenous infusion of human albumin 0.5gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy
In Brief
A Phase 2 clinical trial evaluating Intravenous infusion of human albumin and Saline for Acute Ischemic Stroke. Completed, enrolled 134 participants across 8 sites.
Detailed Summary
The objective of this study is to evaluate the effectiveness and safety of endovascular therapy combined with 25% human albumin in the treatment of acute large vessel occlusive stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
CollaboratorsXuanwu Hospital, Beijing
Timeline
Phase 2CompletedFinished
20252026
First PostedAug 2024
Enrollment StartAug 2024
Primary CompletionDec 2024
Study CompletionMar 2025
TodayJul 2026
First PostedAug 6, 2024
Enrollment StartAug 10, 2024
Primary CompletionDec 20, 2024
Study CompletionMar 15, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.9 years ago
Interventions
Intravenous infusion of human albumindrug
Administer 0.5g/kg of 25% human albumin intravenously as soon as possible within 60 minutes after randomization. And administer 0.5g/kg of 25% ALB intravenously every day on the second, third, and fourth days after randomization.
Salinedrug
Equivalent volume of isotonic saline control